DRMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DRMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-03-26), Dermata Therapeutics's share price is $1.35. Dermata Therapeutics's GF Value is $0.00. Therefore, Dermata Therapeutics's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Dermata Therapeutics is Not Valued.
The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.
To calculate this value, GuruFocus follows these steps:
GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.
Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
Dermata Therapeutics (NAS:DRMA) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) A sufficient margin of safety exists only when the stock is undervalued.
Dermata Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 1.35 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Dermata Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Brittany Bradrick | director | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Gerald T Proehl | 10 percent owner, officer: Pres., CEO and Chairman | |
Van Hoose Kyri K. | officer: Chief Financial Officer | C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Mary Fisher | director | C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
David F Hale | director | 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024 |
Steven J Mento | director | C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804 |
Wendell Wierenga | director | C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555 |
Kathleen D. Scott | director | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Thomas Insley | officer: Chief Financial Officer | SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010 |
Bedoya-toro Munera Maria E | officer: Senior VP | 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Andrew Seth Sandler | director | 1301 2ND AVE, SEATTLE WA 98101 |
Christopher J. Nardo | officer: Senior VP, Development | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Proehl Investment Ventures Llc | 10 percent owner | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130 |
From GuruFocus
By ACCESSWIRE • 09-06-2024
By GuruFocus News • 11-15-2024
By ACCESSWIRE • 02-12-2024
By ACCESSWIRE • 10-09-2024
By ACCESSWIRE • 11-16-2023
By ACCESSWIRE • 11-16-2023
By ACCESSWIRE • 12-03-2024
By ACCESSWIRE • 12-10-2024
By ACCESSWIRE • 07-17-2024
By ACCESSWIRE • 09-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.